Protocol - Disease Progression and Regression - 12-18 Years
Description
The Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS) can be used to evaluate the progression of mitochondrial disease. There are three versions of the NPMDS, each for a specific age range (0-24 months, 2-11 years, and 12-18 years). The NMDAS is for adult patients over 16 years. The investigators from Newcastle University recommend that if the child experiences early onset of a mitochondrial disease in childhood, the NPMDS 12-18 year scale should be used. If an adolescent experiences onset of a mitochondrial disease, the investigators recommend switching to the NMDAS scale at 16 years.
The scales allow for standardization of patient assessment and to improve accurate data collection. The scales are composed of multiple domains: Current Function, System Specific Involvement, Current Clinical Assessment, and Quality of Life. Almost all questions provide a score which ranges from 0-3, with the following representations: 0 is normal, 1 is mild, 2 is moderate, and 3 is severe. Examples of severity for each question are provided. Depending on the domain, the questions are either self- or interviewer-administrated, based on a provider’s clinical assessment or medical records. There is a manual for each scale, which details the administration, process, and scoring instructions.
Specific Instructions
To maximize consistency, the authors of the scales state it is essential that clinicians adhere to the scale instructions. They also advise the scales be administrated by clinicians with experience in the care of patients with mitochondrial disease and that the scale is given every 6 months for children under 2 years of age and at 6- to 12-month intervals for older children and adults.
Availability
Protocol
The Newcastle Paediatric Mitochondrial Disease Scale (NPMDS)
12 - 18 years
Date of assessment:
Age at assessment:
Parental consanguinity:
Age at presentation:
Age at clinical diagnosis:
Clinical diagnosis:
Genotype if known:
Biochemical phenotype if known:
Basis of clinical diagnosis e.g. MRI, blood / CSF lactate
Information regarding pregnancy
• reduced fetal movements _______
• cardiomyopathy on antenatal scans _______
• abnormalities on fetal anomaly scan _______
• other:
Neonatal information:
• gestational age _______
• delivery method (NVD vs instrumental vs C/S) _______
• birth weight _______
• resuscitation and ventilation _______
Scores: Sections I-III:
Section IV:
Section I: Function
Rate function during the preceding 4 week period only according to patient and / or caregiver interview. Indicate the score that best fits patient’s functional status independently of the nature of the signs.
1. Vision (with usual glasses)
- Normal. No parental / patient concerns
- Mild. Difficulty with small print or text on the television
- Moderate. Difficulty outside the home (e.g. bus numbers, road signs or shopping)
- Severe. Difficulty recognising faces or unable to navigate without help or registered blind
2. Hearing
- Normal
- Mild. Mild deafness (e.g. missing words in presence of background noise)
- Moderate. Hearing impaired but fully corrected with hearing aid
- Severe. Poor hearing even with aid or reliant on non-verbal communication
3. Communication
- Normal
- Mild. Mild speech difficulties but easily understood and rarely asked to repeat things
- Moderate. Speech poorly understood by strangers and frequently asked to repeat things
- Severe. Speech not understood by family or friends and / or requires communication aid
4. Feeding
- Normal
- Mild. Choking / vomiting / anorexia resulting in reduced intake or swallowing difficulties requiring dietary adaptations
- Moderate. Supplementary enteral feeding or recurrent aspiration pneumonia
- Severe. Exclusive enteral feeding (gastrostomy / NG tube). Nil by mouth
5. Self-care (personal hygiene, dressing, utensil use e.g. for feeding)
- Normal
- Mild. Slow and / or clumsy self-care requiring extra time or effort. Requires help with some tasks
- Moderate. Requires help with most tasks but retains some independent selfcare function
- Severe. Requires one to one assistance
6. Mobility
- Normal
- Mild. Difficulty walking up stairs or inclines
- Moderate. Requires support (stick / frame / callipers) to walk on the flat
- Severe. Wheelchair dependent
7. Educational Achievement
- Normal. Academic achievement comparable to peers in mainstream school
- Mild. Struggling to remain in mainstream school
- Moderate. Attending special school
- Severe. Not attending school primarily due to illness
Section II: System Specific Involvement
Rate system specific involvement during the preceding 12 month period only according to patient and / or caregiver, clinician’s knowledge and clinical notes.
1. Seizures
- None
- Mild. Myoclonic or absence seizures only or < 1 generalised tonic-clonic seizure each month
- Moderate. > 5 generalized tonic-clonic seizures/month or > 20 absence or myoclonic seizures/month
- Severe. Status epilepticus
2. Encephalopathy
- None
- Mild. Single episode of personality change, excessive sleepiness, confusion or disorientation
- Moderate. Obtunded or >2 encephalopathic episodes/year
- Severe. Life-threatening encephalopathy- requires artificial ventilation
3. Stroke-like Episodes
- None
- Mild. Transient motor symptoms lasting < 24 hours
- Moderate. Single stroke-like episode (> 24 hours)
- Severe. Multiple stroke-like episodes (> 24 hours each)
4. Gastrointestinal
- Normal
- Mild. Mild constipation or unexplained vomiting / diarrhoea < 1/week
- Moderate. Moderate constipation (some relief with laxative treatment) or unexplained vomiting / diarrhoea > 3/week
- Severe. Severe constipation (no relief with laxative treatment) or unexplained vomiting / diarrhoea every day or surgical intervention for dysmotility
5. Endocrine
- Normal
- Mild. Biochemical evidence of impaired function
- Moderate. Endocrine failure requiring replacement therapy
- Severe. Endocrine decompensation (e.g. diabetic ketoacidosis, Addisonian crisis)
6. Respiratory
- Normal
- Mild. Abnormal respiration not requiring hospitalization
- Moderate. Abnormal respiration requiring hospitalisation but not ventilation
- Severe. Abnormal respiration requiring artificial ventilation
7. Cardiovascular
- Normal
- Mild. Asymptomatic ECG change
- Moderate. Abnormal echocardiogram (e.g. cardiomegaly) or sustained / symptomatic arrhythmia on ECG
- Severe. Decompensated cardiomyopathy or requiring pacing device / defibrillator / ablation
8. Renal
- Normal
- Mild. Impaired function but no change in diet or therapy required
- Moderate. Impaired function requiring restricted protein diet
- Severe. Failure requiring transplant / dialysis
9. Liver
- Normal
- Mild. Mildly impaired Liver Function Tests (LFTs). No symptoms of hepatic failure
- Moderate. Impaired LTFs with symptoms (e.g. jaundice, oedema)
- Severe. Failure requiring hospitalisation and / or transplantation
10. Blood
- Normal
- Mild. Anaemia only
- Moderate. Asymptomatic pancytopenia
- Severe. Pancytopenia requiring regular transfusion / transplantation
Section III: Current Clinical Assessment
Rate current status according to the clinician’s examination performed at the time of assessment unless otherwise stated in the question.
1. Growth (ht and weight) over preceding 6 months
- Normal. Following normal growth trajectory
- Mild. Height or weight or both less than 2nd centile but growing parallel to it
- Moderate. Height or weight or both crossing one centile
- Severe. Height or weight or both crossing ≥ 2 centiles or less than 2nd centile with divergent trajectory
2. Development over preceding 12 months Score:____
3. Vision with usual glasses. Acuity is based on vision in the better eye
- Normal. Visual acuity better than or equal to 6/12 or normal fixation and tracking
- Mild. Acuity worse than 6/12 but better than or equal to 6/18 or no fixation on small objects
- Moderate. Acuity worse than 6/18 but better than or equal to 6/60 or impaired fixation on large brightly coloured objects
- Severe. Acuity worse than 6/60 or no response to light or visual threat or unable to finger count
4. Ptosis and Eye Movement
- Normal
- Mild. Gaze evoked nystagmus or unilateral ptosis or impaired eye movement at extremities
- Moderate. Intermittent nystagmus at rest or bilateral ptosis not obscuring pupils or restriction of >50% eye movement
- Severe. Continuous nystagmus at rest or bilateral ptosis obscuring pupils or only a flicker of eye movement
5. Myopathy
- Normal
- Mild. Mild symmetrical weakness of hip and / or shoulder girdle only
- Moderate. Moderate symmetrical weakness (proximal > distal) limiting mobility
- Severe. Wheelchair dependent or respiratory compromise due to myopathy
6. Ataxia
- Normal
- Mild. Ataxic gait but walks unaided or mild upper limb dysmetria
- Moderate. Gait abnormality requiring assistance or severe upper limb dysmetria
- Severe. Wheelchair dependent or unable to feed due to ataxia
7. Pyramidal
- Normal
- Mild. Mild hemiplegia allowing unaided ambulation
- Moderate. Moderate hemiplegia allowing ambulation with aids
- Severe. Wheelchair dependent due to hemi / tetraplegia
8. Extrapyramidal
- Normal
- Mild. Focal dystonia or unilateral extrapyramidal tremor / bradykinesia
- Moderate. Generalised dystonia or bilateral extrapyramidal tremor / bradykinesia
- Severe. Wheelchair dependent due to extrapyramidal disorder
9. Neuropathy
- Normal.
- Mild. Areflexia only
- Moderate. Sensory ataxia or motor impairment (distal weakness) but mobile
- Severe. Reliant on mobility aids primarily due to neuropathy
Section IV: Quality of Life- Parent Completed
This survey asks for your views about your child’s recent health. Please answer every question by marking an ‘x’ in the box next to the phrase which best describes your answer.
1) During the past 4 weeks, how would you rate your child’s overall health?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
2) During the past 4 weeks, how much did your child’s physical health problems limit
their physical activities (such as walking or playing with friends)?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
3) During the past 4 weeks, how much did your child’s health problems limit their
everyday life (such as attending school, caring for themselves) compared with a
person of the same age in perfect health?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
4) During the past 4 weeks, how much energy did your child have?
[ ] None
[ ] A little
[ ] Some
[ ] Quite a lot
[ ] Very much
5) During the past 4 weeks, how much bodily pain/discomfort did your child have?
[ ] Very much
[ ] Quite a lot
[ ] Some
[ ] A little
[ ] None
6) During the past 4 weeks, how much was your child bothered by emotional
problems?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
7) During the past 4 weeks, how satisfied did your child feel with their abilities, looks,
relationships with other people and life in general?
[ ] Very dissatisfied
[ ] Quite dissatisfied
[ ] Neither dissatisfied or satisfied
[ ] Quite satisfied
[ ] Very satisfied
8) During the past 4 weeks, how would you rate your child’s behaviour compared
with other children his / her age?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
9) During the past 4 weeks, how would you rate your child’s ability to interact with
other people (e.g. making friends, talking to other children / strangers) compared with
other children his / her age?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
10) During the past 4 weeks, how much were you (the parent / carer) bothered by
emotional problems (e.g. feelings of anxiety, sadness) as a result of your child’s
illness?
[ ] Very
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
11) During the past 4 weeks, how much was your time limited as a result of your
child’s illness?
[ ] Very
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
12) During the past 4 weeks, how much were your family’s activities limited or
interrupted as a result of your child’s illness?
[ ] Very
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
13) During the past 6 months, what has been the financial cost of your child’s illness?
[ ] Very expensive
[ ] Quite expensive
[ ] Moderately expensive
[ ] Little additional cost
[ ] No additional cost
14) During the past 4 weeks, how would you rate your family’s ability to get along
with one another?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
15) During the past 4 weeks, how often did your child’s illness have a positive effect
on your child, you or your family (e.g. being treated well due to illness, meeting new
people)?
[ ] Never
[ ] Occasionally
[ ] Sometimes
[ ] Quite a lot
[ ] Most of the time
Section D: Quality of Life- Self Completed
12-16 years
This survey asks about how you have been feeling recently. Please answer every
question by marking an ‘x’ in the box next to the phrase which best describes your
answer.
1) During the past 4 weeks, how would you rate your overall health?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
2) During the past 4 weeks, how much did your physical health problems limit your
physical activities (such as walking or going out with friends)?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
3) During the past 4 weeks, how much did your health problems limit your everyday
life (such as going to school, caring for yourself) compared with a person of your age
in perfect health?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
4) During the past 4 weeks, how much energy did you have?
[ ] None
[ ] A little
[ ] Some
[ ] Quite a lot
[ ] Very much
5) During the past 4 weeks, how much pain or discomfort did you have?
[ ] Very much
[ ] Quite a lot
[ ] Some
[ ] A little
[ ] None
6) During the past 4 weeks, how much were you bothered by emotional problems
(e.g. feeling sad or frightened)?
[ ] Very much
[ ] Quite a lot
[ ] Somewhat
[ ] A little
[ ] Not at all
7) During the past 4 weeks, how satisfied did you feel with your abilities, looks,
relationships with other people and life in general?
[ ] Very dissatisfied
[ ] Quite dissatisfied
[ ] Neither dissatisfied or satisfied
[ ] Quite satisfied
[ ] Very satisfied
8) During the past 4 weeks, how would you rate your behaviour compared with other
people your age?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
9) During the past 4 weeks, how easy did you find it to get on with other people (e.g.
making friends, talking to friends / strangers) compared with other people your age?
[ ] Very hard
[ ] Hard
[ ] OK
[ ] Easy
[ ] Very easy
10) During the past 4 weeks, how would you rate your family’s ability to get along
with one another?
[ ] Very poor
[ ] Poor
[ ] Fair
[ ] Good
[ ] Very good
11) During the past 4 weeks, how often did your illness have a positive effect on you
or your family (e.g. being treated well because of your illness, meeting new people)?
[ ] Never
[ ] Occasionally
[ ] Sometimes
[ ] Quite a lot
[ ] Most of the time
Personnel and Training Required
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS) should be administered by clinicians, preferably with experience in caring for patients with mitochondrial disease or other rare genetic conditions.
Equipment Needs
None.
Requirements
Requirement Category | Required |
---|---|
Major equipment | No |
Specialized training | Yes |
Specialized requirements for biospecimen collection | No |
Average time of greater than 15 minutes in an unaffected individual | Yes |
Mode of Administration
Self- or proxy-administered questionnaire
Lifestage
Child, Adolescent
Participants
Children and adolescents ages 12-18 years old
Selection Rationale
The Rare Genetic Conditions Working Group (WG) selected the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS) because mitochondrial disorders have a wide array of symptoms making this measure potentially extensible to other progressive disorders. In addition, rare genetic disorders can be associated with secondary mitochondrial dysfunction and overlapping symptoms. Although these scales were developed for mitochondrial diseases, the WG acknowledges data from these scales can be beneficial for other rare genetic conditions, such as inborn errors of metabolism, storage disorders, and nonmitochondrial myopathies.
Language
English
Standards
Standard | Name | ID | Source |
---|---|---|---|
Human Phenotype Ontology | Pace of progression | HP:0003679 | HPO |
caDSR Form | PhenX PX220703 - Disease Progression And Regression 12-18 Years | 6201251 | caDSR Form |
Derived Variables
None
Process and Review
Not applicable.
Protocol Name from Source
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS), 12-18 years
Source
Newcastle University. Newcastle Paediatric Mitochondrial Disease Scale (NPMDS)
12-18 years. Available at bsu.ncl.ac.uk/pdfs/12-18_paed.pdf.
General References
Enns, G. M., Moore, T., Le, A., Atkuri, K., Shah, M. K., Cusmano-Ozog, K., Niemi, A. K., & Cowan, T. M. (2014). Degree of glutathione deficiency and redox imbalance depend on subtype of mitochondrial disease and clinical status. PLoS One, 9(6), e100001. doi:10.1371/journal.pone.0100001
Phoenix, C., Schaefer, A. M., Elson, J. L., Morava, E., Bugiani, M., Uziel, G., Smeitink, J. A., Turnbull, D. M., & McFarland, R. (2006). A scale to monitor progression and treatment of mitochondrial disease in children. Neuromuscular disorders: NMD, 16(12), 814-820.
Protocol ID
220703
Variables
Export VariablesVariable Name | Variable ID | Variable Description | dbGaP Mapping | |
---|---|---|---|---|
PX220703_Disease_ProgressionRegression_12to18_Abnormalities_FetalScan | ||||
PX220703110000 | abnormalities on fetal anomaly scan | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Abnormalities_Specify | ||||
PX220703120000 | Please specify | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Age | ||||
PX220703020000 | Age at assessment: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Basis_Diagnosis | ||||
PX220703080000 | Basis of clinical diagnosis e.g. MRI, blood more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Biochemical_Phenotype | ||||
PX220703070000 | Biochemical phenotype if known: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Ataxia | ||||
PX220703430000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Development | ||||
PX220703390000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Extrapyramidal | ||||
PX220703450000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_GrowthWeight | ||||
PX220703380000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Myopathy | ||||
PX220703420000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Neuropathy | ||||
PX220703460000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_PtosisEyeMovement | ||||
PX220703410000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Pyramidal | ||||
PX220703440000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentClinical_Vision | ||||
PX220703400000 | Rate current status according to the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Communication | ||||
PX220703230000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Education | ||||
PX220703270000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Feeding | ||||
PX220703240000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Hearing | ||||
PX220703220000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Mobility | ||||
PX220703260000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_SelfCare | ||||
PX220703250000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_CurrentFunction_Vision | ||||
PX220703210000 | Rate function during the preceding 4 week more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Date | ||||
PX220703010000 | Date of assessment: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Genotype | ||||
PX220703060000 | Genotype if known: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Neonatal_BirthWeight | ||||
PX220703160000 | birth weight in kg | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Neonatal_DeliveryMethod | ||||
PX220703150000 | delivery method (NVD vs instrumental vs C/S) | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Neonatal_GestationalAge | ||||
PX220703140000 | gestational age in weeks | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Neonatal_ResuscitationVentilation | ||||
PX220703170000 | Resuscitation and ventilation | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Neonatal_Specify | ||||
PX220703180000 | Specify | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_ParentalAge_AgeDx | ||||
PX220703050000 | Age at clinical diagnosis: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Parental_AgePresentation | ||||
PX220703040000 | Age at presentation: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Parental_Consanguinity | ||||
PX220703030000 | Parental consanguinity: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Pregnancy_Cardiomyopathy_Antenatal | ||||
PX220703100000 | cardiomyopathy on antenatal scans | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Pregnancy_Cardiomyopathy_PregnancyOther | ||||
PX220703130000 | Other | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_AbilitiesLooks | ||||
PX220703680000 | During the past 4 weeks, how satisfied did more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_Behaviour | ||||
PX220703690000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_EmotionalProblems | ||||
PX220703670000 | During the past 4 weeks, how much were you more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_Energy | ||||
PX220703650000 | During the past 4 weeks, how much energy did more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_Family | ||||
PX220703710000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_Friends | ||||
PX220703700000 | During the past 4 weeks, how easy did you more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_HealthLimits | ||||
PX220703640000 | During the past 4 weeks, how much did your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_OverallHealth | ||||
PX220703620000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_Pain | ||||
PX220703660000 | During the past 4 weeks, how much pain or more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_PhysicalProblems | ||||
PX220703630000 | During the past 4 weeks, how much did your more | Variable Mapping | ||
PX220703_Disease_ProgressionRegression_12to18_QOLSelf_PositiveEffects | ||||
PX220703720000 | During the past 4 weeks, how often did your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_AbilitiesLooks | ||||
PX220703530000 | During the past 4 weeks, how satisfied did more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_ActivitiesLimited | ||||
PX220703580000 | During the past 4 weeks, how much were your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_Behavior | ||||
PX220703540000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_EmotionalProblems | ||||
PX220703520000 | During the past 4 weeks, how much was your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_Energy | ||||
PX220703500000 | During the past 4 weeks, how much energy did more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_FinancialCost | ||||
PX220703590000 | During the past 6 months, what has been the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_GetAlong | ||||
PX220703600000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_Interactions | ||||
PX220703550000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_Limits | ||||
PX220703490000 | During the past 4 weeks, how much did your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_OverallHealth | ||||
PX220703470000 | During the past 4 weeks, how would you rate more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_Pain | ||||
PX220703510000 | During the past 4 weeks, how much bodily more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_ParentEmotions | ||||
PX220703560000 | During the past 4 weeks, how much were you more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_PhsyicalActivities | ||||
PX220703480000 | During the past 4 weeks, how much did your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_PositiveEffects | ||||
PX220703610000 | During the past 4 weeks, how often did your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_QOL_TimeLimited | ||||
PX220703570000 | During the past 4 weeks, how much was your more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Reduced_FetalMovement | ||||
PX220703090000 | reduced fetal movements | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Score_SectionIV | ||||
PX220703200000 | Score Section IV: | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_Score_SectionsI_III | ||||
PX220703190000 | Score Sections I-III | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Blood | ||||
PX220703370000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Cardiovascular | ||||
PX220703340000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Encephalopathy | ||||
PX220703290000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Endocrine | ||||
PX220703320000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Gastrointestinal | ||||
PX220703310000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Liver | ||||
PX220703360000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Renal | ||||
PX220703350000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Respiratory | ||||
PX220703330000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_Seizures | ||||
PX220703280000 | Rate system specific involvement during the more | N/A | ||
PX220703_Disease_ProgressionRegression_12to18_SystemInvolvement_StrokeLike | ||||
PX220703300000 | Rate system specific involvement during the more | N/A |
Measure Name
Disease Progression and Regression
Release Date
April 30, 2015
Definition
This measure determines the impact of disease on an individual over time.
Purpose
This measure is used to assess the presence and degree of symptoms over time. Rare genetic diseases, such as mitochondrial disorders and mucopolysaccharidosis (MPS), can be associated with symptoms that become more severe over time and may result in a regression of some physical abilities. This measure can be used to quantify such changes to determine the natural course of disease(s) as well as contribute to longitudinal or therapeutic intervention studies.
Keywords
Newcastle Paediatric Mitochondrial Disease Scale, NPMDS, Newcastle Mitochondrial Disease Adult Scale, NMDAS, mitochondria, Developmental Delay, Intellectual Delay, disease, disease scale, progression, regression
Measure Protocols
Protocol ID | Protocol Name |
---|---|
220701 | Disease Progression and Regression - 0-24 Months |
220702 | Disease Progression and Regression - 2-11 Years |
220703 | Disease Progression and Regression - 12-18 Years |
220704 | Disease Progression and Regression - Adult |
Publications
There are no publications listed for this protocol.